Articles Referencing AGEN
Data on ArQule's ARQ 092 - Analyst Blog
4/10/2013, 5:10 pm from Zacks.com in Investing, Business, Stocks
Researchers recently presented data on ArQule's
( ARQL ) ARQ 092 at
the American Association for Cancer Research (AACR) Annual Meeting
held in Washington, D.C. The data revealed that the... Read >>
Spectrum Progresses with SPI-2012 - Analyst Blog
4/9/2013, 5:09 pm from Zacks.com in Investing, Business, Stocks
Spectrum Pharmaceuticals ( SPPI ) recently
initiated a phase II study on SPI-2012 (LAPS-GCSF). SPI-2012 is
being developed for the treatment of chemotherapy-induced
neutropenia which... Read >>
Acorda Reports Data on Epilepsy Drug - Analyst Blog
3/26/2013, 4:27 pm from Zacks.com in Investing, Business, Stocks
Acorda Therapeutics, Inc. ( ACOR ) recently
announced data from a phase I study evaluating its epilepsy
candidate, diazepam nasal spray. The company is developing diazepam
nasal spray for... Read >>
SPPI Acquires Late-Stage Candidate - Analyst Blog
3/18/2013, 6:45 pm from Zacks.com in Investing, Business, Stocks
Spectrum Pharmaceuticals ( SPPI ) recently
acquired global development and commercialization rights to
Ligand Pharmaceuticals Inc 's ( LGND )
Captisol-enabled, propylene glycol-free... Read >>
XOMA Posts Narrower Loss - Analyst Blog
3/14/2013, 1:16 pm from Zacks.com in Investing, Business, Stocks
XOMA Corporation ( XOMA ) reported
fourth-quarter 2012 loss of 15 cents per share, narrower than the
year-ago loss of 36 cents and the Zacks Consensus Estimate of a
loss of 24 cents. Lower... Read >>
Spectrum Guides Lower 2013 Revenue - Analyst Blog
3/13/2013, 4:11 pm from Zacks.com in Investing, Business, Stocks
Spectrum Pharmaceuticals ( SPPI ) recently
provided its first quarter and full year 2013 revenue guidance. The company expects Fusilev sales in the first quarter of 2013
in the range of... Read >>
Update on Elan's Plans - Analyst Blog
3/11/2013, 5:08 pm from Zacks.com in Investing, Business, Stocks
Elan Corporation plc ( ELN ) recently provided
an update on its proposed $1billion share repurchase program which
is expected to be implemented after the close of the Tysabri
(multiple... Read >>
Acorda Presents GGF2 Data - Analyst Blog
3/8/2013, 4:15 pm from Zacks.com in Investing, Business, Stocks
Acorda Therapeutics, Inc. ( ACOR ) recently
announced data from a phase I trial (n=40) evaluating the safety,
tolerability and exploratory efficacy of glial growth factor 2
(GGF2) in... Read >>
Elan to Share Tysabri Proceeds - Analyst Blog
3/7/2013, 5:39 pm from Zacks.com in Investing, Business, Stocks
Elan Corporation plc 's ( ELN ) Board of
Directors recently approved the initiation of a cash dividend
policy. The dividend policy will enable the company's shareholders
to enjoy long-term... Read >>
Aegerion Incurs Wider Loss - Analyst Blog
3/7/2013, 1:14 pm from Zacks.com in Investing, Business, Stocks
Aegerion Pharmaceuticals, Inc. ( AEGR ) reported fourth
quarter 2012 net loss per share of 86 cents, wider than the Zacks
Consensus Estimate of a loss of 62 cents and the year-ago loss... Read >>
Narrower-Than-Expected Loss at OSIR - Analyst Blog
3/7/2013, 8:30 am from Zacks.com in Investing, Business, Stocks
Osiris Therapeutics Inc. ( OSIR ) reported a
fourth-quarter loss of 8 cents per share, narrower than the Zacks
Consensus Estimate of a loss of 15 cents. However, year-ago
earnings were 15... Read >>
Vertex Flu Drug Shows Promise - Analyst Blog
3/6/2013, 12:20 pm from Zacks.com in Investing, Business, Stocks
Vertex Pharmaceuticals ( VRTX ) recently
presented promising data on its influenza candidate, VX-787. The
company presented results from a double-blind, randomized,
placebo-controlled phase... Read >>
Wider Loss at InterMune - Analyst Blog
2/22/2013, 12:30 pm from Zacks.com in Investing, Business, Stocks
InterMune Inc. 's ( ITMN ) fourth-quarter
loss per share of 91 cents was wider than the Zacks Consensus
Estimate of a loss of 86 cents and the year-ago loss of 73 cents
per share. The wider... Read >>
Savient to Promote Sobi's Kineret - Analyst Blog
2/21/2013, 11:50 am from Zacks.com in Investing, Business, Stocks
Savient Pharmaceuticals, Inc. ( SVNT ) recently
entered into an agreement with Swedish Company Sobi for the
co-promotion of Kineret (anakinra) in the US. Kineret is approved for... Read >>
ALIOF Candidate Approved in Japan - Analyst Blog
2/20/2013, 6:45 pm from Zacks.com in Investing, Business, Stocks
Actelion Ltd . ( ALIOF ) recently
announced the receipt of Japan's Ministry of Health, Labor and
Welfare approval for epoprostenol "ACT" for the treatment of
pulmonary arterial... Read >>